Science Times Observer
SEE OTHER BRANDS

Your top news on science and technology

Science Times Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.

Press releases published on May 7, 2025

ESCO Reports Second Quarter Fiscal 2025 Results

ESCO Reports Second Quarter Fiscal 2025 Results

St. Louis, May 07, 2025 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second quarter ended March 31, 2025 (Q2 2025). Operating Highlights Q2 2025 Sales increased $16.4 million (7 …

Coherent Corp. Reports Third Quarter Fiscal 2025 Results

Coherent Corp. Reports Third Quarter Fiscal 2025 Results

Q3 REVENUE OF $1.50B, INCREASED 24% Y/Y Q3 GAAP GROSS MARGIN OF 35.2%, INCREASED 491 bps Y/Y; Q3 NON-GAAP GROSS MARGIN OF 38.5%, INCREASED 490 bps Y/Y Q3 GAAP EPS OF $(0.11), IMPROVED $0.18 Y/Y; Q3 NON-GAAP EPS OF $0.91, IMPROVED $0.53 Y/Y SAXONBURG, Pa., …

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength …

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities …

GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires

GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le …

Earlyworks Co., Ltd. Announces Receipt of Nasdaq Delisting Determination and Plan to Request a Hearing before the Nasdaq Hearings Panel

Earlyworks Co., Ltd. Announces Receipt of Nasdaq Delisting Determination and Plan to Request a Hearing before the Nasdaq Hearings Panel

TOKYO, May 07, 2025 (GLOBE NEWSWIRE) -- Earlyworks Co., Ltd. (Nasdaq: ELWS) (the “Company” or “Earlyworks”), a Japanese company operating its proprietary private blockchain technology, Grid Ledger System (“GLS”), today announced that it received a staff …

Veeco Announces Over $35 Million in Advanced Packaging Lithography System Orders From IDM & OSAT Customers

Veeco Announces Over $35 Million in Advanced Packaging Lithography System Orders From IDM & OSAT Customers

PLAINVIEW, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced its received over $35 million of orders for its AP300™ Lithography systems in recent quarters from a wide-range of IDM and OSAT customers. The orders …

WANG & LEE GROUP, Inc. Bid Price Deficiency

WANG & LEE GROUP, Inc. Bid Price Deficiency

HONG KONG, May 07, 2025 (GLOBE NEWSWIRE) -- WANG …

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Context …

Fortinet Reports First Quarter 2025 Financial Results

Fortinet Reports First Quarter 2025 Financial Results

Highlights Total revenue of $1.54 billion, up 14% year over year Product revenue of $459 million, up 12% year over year Billings of $1.60 billion, up 14% year over year1 Unified SASE ARR2 up 26% and Security Operations ARR2 up 30%, year over year Record …

Matrix Service Company Reports Fiscal Year 2025 Third Quarter Results

Matrix Service Company Reports Fiscal Year 2025 Third Quarter Results

TULSA, Okla., May 07, 2025 (GLOBE NEWSWIRE) -- Matrix Service Company (Nasdaq: MTRX), a leading provider of engineering and construction services to the energy and industrial markets, today announced results for the third quarter of fiscal 2025 ended March …

Alto Ingredients, Inc. Reports First Quarter 2025 Results

Alto Ingredients, Inc. Reports First Quarter 2025 Results

- Beverage-grade Liquid CO2 Processor Acquisition and Corporate Reorganization Deliver Improved Year-over-Year Gross Margin and Adjusted EBITDA - PEKIN, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and …

LiveRamp to Discuss Fiscal 2025 Fourth Quarter and Full Year Results

LiveRamp to Discuss Fiscal 2025 Fourth Quarter and Full Year Results

SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), a leading data collaboration platform, today announced that its fiscal 2025 fourth quarter and full year earnings release will be issued on Wednesday, May 21, 2025 after the financial …

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

-  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid …

red violet Announces First Quarter 2025 Financial Results

red violet Announces First Quarter 2025 Financial Results

BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the quarter ended March 31, 2025. “We are extremely pleased to report another …

Crane NXT Reports First Quarter 2025 Results

Crane NXT Reports First Quarter 2025 Results

Completes Acquisition of De La Rue Authentication, a Global Leader in Security and Authentication Technologies Increases Sales Growth Guidance to 6% to 8% for Full Year 2025; Maintaining Full Year EPS Guidance of $4.00 to $4.30 WALTHAM, Mass., May 07, 2025 …

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

HeartCore to Present at Sidoti Micro-Cap Virtual Conference on May 21, 2025 at 11:30 a.m. ET

HeartCore to Present at Sidoti Micro-Cap Virtual Conference on May 21, 2025 at 11:30 a.m. ET

NEW YORK and TOKYO, May 07, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, will be virtually presenting and holding one- …

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of $47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net …

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service